Durable complete response rates following radiotherapy and immunotherapy combination in recurrent and metastatic head and neck squamous cell carcinoma: A retrospective single centre cohort study
Name:
35737806.pdf
Size:
855.7Kb
Format:
PDF
Description:
Identified with Open Access button
Affiliation
The Christie NHS Foundation Trust, Manchester, UKIssue Date
2022
Metadata
Show full item recordCitation
Khera R, Feeney L, Swinton M, Rack S, Sykes A, Metcalf R. Durable complete response rates following radiotherapy and immunotherapy combination in recurrent and metastatic head and neck squamous cell carcinoma: A retrospective single‐centre cohort study. Clinical Otolaryngology. Wiley; 2022.Journal
Clinical OtolaryngologyDOI
10.1111/coa.13954PubMed ID
35737806Additional Links
https://dx.doi.org/10.1111/coa.13954Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1111/coa.13954
Scopus Count
Collections
Related articles
- ["Immunotherapy in head and neck squamous cell carcinoma"].
- Authors: Marret G, Borcoman É, Le Tourneau C
- Issue date: 2021 Apr
- The biology of combination immunotherapy in recurrent metastatic head and neck cancer.
- Authors: Yuan X, Yi M, Zhang W, Xu L, Chu Q, Luo S, Wu K
- Issue date: 2021 Jul
- [Ⅰ. Photo-Immunotherapy for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck].
- Authors: Sano D, Oridate N
- Issue date: 2023 Jul
- Immunotherapy in Patients with Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck.
- Authors: Łasińska I, Kolenda T, Teresiak A, Lamperska KM, Galus Ł, Mackiewicz J
- Issue date: 2019
- Real-world data of immunotherapy from China in recurrent or metastatic head and neck squamous cell carcinoma.
- Authors: Zhang X, Wang P, Chai Y, Zhou X, Li P, Wang X
- Issue date: 2024 Jan-Feb